Acceleron Pharma Inc. (XLRN): Price and Financial Metrics
XLRN Price/Volume Stats
| Current price | $178.75 | 52-week high | $189.99 |
| Prev. close | $179.68 | 52-week low | $108.82 |
| Day low | $177.06 | Volume | 7,884,200 |
| Day high | $179.85 | Avg. volume | 572,759 |
| 50-day MA | $168.57 | Dividend yield | N/A |
| 200-day MA | $137.67 | Market Cap | 10.93B |
XLRN Stock Price Chart Interactive Chart >
Acceleron Pharma Inc. (XLRN) Company Bio
Acceleron Pharma XLRN is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Latest XLRN News From Around the Web
Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.
Sphinx Trading LP Takes $120,000 Position in Acceleron Pharma Inc. (NASDAQ:XLRN)Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced [] |
Merck Closes Biggest Biotech Deal of the YearThe purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire. |
Merck completes tender offer for $11B Acceleron Pharma acquisitionNo summary available. |
Acceleron Pharma (NASDAQ:XLRN) vs. Brickell Biotech (NASDAQ:BBI) Head to Head ComparisonAcceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% [] |
Fulton Bank N.A. Buys Shares of 1,507 Acceleron Pharma Inc. (NASDAQ:XLRN)Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to [] |
XLRN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 48.82% |
| 5-year | 350.37% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 141.31% |
| 2019 | 21.75% |
Continue Researching XLRN
Here are a few links from around the web to help you further your research on Acceleron Pharma Inc's stock as an investment opportunity:Acceleron Pharma Inc (XLRN) Stock Price | Nasdaq
Acceleron Pharma Inc (XLRN) Stock Quote, History and News - Yahoo Finance
Acceleron Pharma Inc (XLRN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...